(FMD Impact Registry) Fibromuscular Dysplasia Findings and Outcomes

Overview

About this study

To describe the clinical, laboratory, pathologic, imaging findings, therapy and outcomes in all patients with Fibromuscular Dysplasia (FMD) and/or segmental arterial mediolysis evaluated at Mayo Clinic retrospectively (back to 01/01/1990) and prospectively (starting 04/13/2016).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Diagnosis of fibromuscular dysplasia (FMD), segmental arterial mediolysis, and/or spontaneous coronary artery dissection (SCAD)

Exclusion Criteria: 

  • Missing records to determine whether or not they have FMD

  • Patients who do not accept to participate in research studies.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Raymond Shields, M.D.

Open for enrollment

Contact information:

Raymond Shields M.D.

(507) 266-3964

shields.raymond@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20304524

Mayo Clinic Footer